Overactive Bladder Clinical Trial
Official title:
Comparison of the Efficacy and Safety of Combination Treatment With Doxazosin Plus TolterodineSR 2 mg vs Doxazosin Plus TolterodineSR 4 mg in Men With an OAB/BPO: Randomized Controlled Study"
NCT number | NCT00922506 |
Other study ID # | 2008-08-092 |
Secondary ID | |
Status | Completed |
Phase | Phase 4 |
First received | |
Last updated | |
Start date | May 2009 |
Est. completion date | June 2014 |
Verified date | November 2019 |
Source | Samsung Medical Center |
Contact | n/a |
Is FDA regulated | No |
Health authority | |
Study type | Interventional |
OAB occurs in approximately 50% to 75% of men with BPO and up to 38% of men with BPO continue
to suffer from OAB after relief the obstruction.Symptoms of OAB are more bothersome than the
voiding complaints of slow stream and hesitancy. However, the patients with both BPO and OAB
are often not treated with muscarinic receptor antagonists due to concern that they will
experience acute urinary retention.
Tolterodine is a potent and pure muscarinic receptor antagonist that was developed
specifically for the treatment of overactive bladder. Recently, studies revealed that
tolterodine was effective, safe and well tolerated in adults with OAB and urodynamically
confirmed BPO.However, the optimal dosage of antimuscarinic for the treatment of OAB
coexisting BPO was not yet fully assessed. In real clinical situation, some patients complain
voiding difficulty after addition of antimuscarinics and want to stop antimuscarinics.It is
probable that a lower dosage of antimuscarinics combined with alpha-adrenergic antagonists
can be used safely in OAB patients with BOO, with the same efficacy.
This study is designed to investigate the optimal doses of tolterodine SR in combination with
doxazosin in men with both BOO and OAB based on efficacy, safety, and tolerability.
Status | Completed |
Enrollment | 83 |
Est. completion date | June 2014 |
Est. primary completion date | May 2014 |
Accepts healthy volunteers | No |
Gender | Male |
Age group | 50 Years to 80 Years |
Eligibility |
Inclusion Criteria: - Male aged 50 = and = 80 years - Proven bladder outlet obstruction (BOO, Abrams/Griffith score >20) on urodynamic study - Symptoms of OAB as verified by the 3 day voiding diary, defined by: 1. symptoms of urinary urgency (defined as a level of =3 in a 5 point urgency scale) at least two episode per 24 hours and 2. symptoms of urinary frequency (8 micturitions per 24 hours) - Total International Prostate Symptom Score (IPSS) of 12 or higher - IPSS quality-of-life (QOL) item score of 3 or higher - A rating of the bladder condition at Baseline prior to randomization as "Some Moderate Problems", "Severe Problems", or "Many Severe Problems" on the Patient Perception of Bladder Condition (PPBC) questionnaire. - Ability and willingness to correctly complete the micturition diary and questionnaire - Capable of understanding and having signed the informed consent form after full discussion of the research nature of the treatment and its risks and benefits Exclusion Criteria: - Patients have a baseline post-void residual (PVR) which exceeded 150 mL. - Any condition that is a contraindication for anticholinergic treatment, including uncontrolled narrow-angled glaucoma, urinary retention or gastric retention. - Symptomatic acute urinary tract infection (UTI) during the screening period. - Treatment within the 14 days preceding randomization, or expected to initiate treatment during the study with any anticholinergic drugs and drug treatment for overactive bladder. - A 5-alpha reductase inhibitor if started less than 3 months prior to screening. - Patients with previous urethral, prostate or bladder neck surgery. - Patients with cancer of any type including cancer of the prostate or bladder, uncontrolled medical condition including psychiatric disease or life threatening illness. - Patients with Parkinson's disease, stroke, multiple sclerosis, spinal cord disease. - Patients with suspected neurogenic bladder disorder. - Patients with urethral stricture or bladder neck contracture. - Serum PSA 4ng/ml (only patients with no malignancy by prostate biopsy can be included). |
Country | Name | City | State |
---|---|---|---|
Korea, Republic of | Samsung Medical Center | Seoul |
Lead Sponsor | Collaborator |
---|---|
Samsung Medical Center |
Korea, Republic of,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Numeric change of urgency episodes per 24 hours | 12 weeks of treatment | ||
Secondary | Changes in voiding diary parameters | 12 weeks of treatment | ||
Secondary | Change in symptom questionnaires | 12 weeks | ||
Secondary | Patient-Rated Global Assessments of Treatment Benefit, Satisfaction, and Willingness to Continue | 12 weeks | ||
Secondary | Change of uroflowmetry and PVR | 12 weeks | ||
Secondary | Incidence of acute urinary retention | during all study periods |
Status | Clinical Trial | Phase | |
---|---|---|---|
Recruiting |
NCT04578899 -
"The Effectiveness of Transvertebral Magnetic Neuromodulation in Patients With Detrusor Overactivity"
|
N/A | |
Active, not recruiting |
NCT03556891 -
Pivotal Study of eCoin for Overactive Bladder With Urgency Urinary Incontinence
|
N/A | |
Not yet recruiting |
NCT05977634 -
Transcutaneous Tibial Nerve Stimulation for Idiopathic Overactive Bladder
|
N/A | |
Completed |
NCT01955408 -
Severity of Overactive Bladder Symptoms in Patients After Synergo Treatment
|
N/A | |
Recruiting |
NCT06201013 -
Efficacy and Safety of Vitamin D in the Treatment of OAB-wet in Children
|
N/A | |
Recruiting |
NCT03727711 -
TPTNS: Home vs Hospital Treatment for Overactive Bladder
|
N/A | |
Completed |
NCT00768521 -
A Study to Test the Effects of Tolterodine Tartrate in Patients With Overactive Bladder (0000-107)
|
Phase 1 | |
Completed |
NCT03625843 -
Mindfulness Exercises to Reduce Anxiety and Pain During Urodynamic Testing
|
N/A | |
Completed |
NCT02211846 -
A Study to Evaluate the Pharmacokinetics, Safety and Tolerability of Mirabegron OCAS (Oral Controlled Absorption System) in Pediatric Subjects With Neurogenic Detrusor Overactivity or Overactive Bladder
|
Phase 1 | |
Completed |
NCT02835846 -
Investigation of the Effect of the Female Urinary Microbiome on Incontinence
|
Phase 4 | |
Completed |
NCT02857816 -
PRospective Study to Evaluate EffectivenesS With the NURO™ PErcutaneous Tibial Neuromodulation System in Patients With OAB
|
N/A | |
Withdrawn |
NCT02320201 -
Foot Neuromodulation for Overactive Bladder in Children
|
N/A | |
Completed |
NCT02202031 -
Controlling Urgency Through Relaxation Exercises
|
N/A | |
Completed |
NCT01437670 -
Observational Study to Estimate the Dry Mouth in OAB Patients With Solifenacin
|
N/A | |
Completed |
NCT01458197 -
A Phase 2 Study to Compare the Efficacy and Tolerability of Tarafenacin 0.2 mg and Tarafenacin 0.4 mg to Placebo in Patients Suffering From Overactive Bladder.
|
Phase 2 | |
Not yet recruiting |
NCT01423838 -
Comparison of Solifenacin and Oxybutynin in the Treatment of Overactive Bladder
|
Phase 4 | |
Not yet recruiting |
NCT01409512 -
Evaluation of Autonomic System Before and After Anticholinergic Treatment in Women With Overactive Bladder
|
N/A | |
Withdrawn |
NCT01210859 -
Effects of Antimuscarinic Drugs on Overactive Bladder (OAB) Symptoms After Insertion of Ureteral Stents
|
N/A | |
Terminated |
NCT01758848 -
Physical Therapy for Overactive Bladder
|
N/A | |
Completed |
NCT00910520 -
Botulinum Toxin Type A for the Treatment of Patients With Idiopathic Overactive Bladder With Urinary Incontinence
|
Phase 3 |